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Many molecules that could manipulate cellular function are not practical due to their large size and concomitant undesirable
pharmocokinetic properties. Here Shin et al. describe a bioorthogonal reaction, highly stable boronate ester (HiSBE)
synthesis, and use this reaction to assemble a biologically active molecule from smaller precursors in a physiological context.
The rapid rate of HiSBE synthesis suggests that it may be useful for assembling a wide variety of biologically active molecules
in physiological solutions.Riluzole Enhances Wnt/b-catenin Signaling in Melanoma
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Wnt/b-catenin signaling is a major regulator of melanocyte differentiation. In melanoma, elevated
b-catenin signaling has been correlated with favorable patient outcome and shown to promote
a transcriptional profile consistent with differentiation toward a less proliferative, melanocyte-
like state. Now, Biechele et al. show that riluzole, an FDA-approved drug recently shown to be
efficacious in metastatic melanoma, enhances Wnt/b-catenin signaling and examine effects of
Wnt/b-catenin signaling on melanoma cells. The results of this study, combined with prior data
that b-catenin signaling has complex effects in different cancers, should stimulate further
investigation into the use of riluzole for melanoma as well as other cancer therapies.Inhibition of Huntingtin by a miRNA-like RNAi Mechanism
PAGE 1183
Inhibiting expression of huntingtin (HTT) protein is a promising strategy for treating Huntington’s Disease (HD), but indiscrim-
inant inhibition of both wild-type and mutant alleles may lead to toxicity. An ideal silencing agent would block expression of
mutant HTT while leaving expression of wild-type HTT intact. Hu et al. now explore switching the RNAi mechanism towards
that used by miRNAs by introducing mismatched bases, which leads to potent and highly selective inhibition of mutant HTT
expression in patient-derived cells. Potent allele-selective inhibition of HTT by mismatched RNAs provides a new option for
developing HD therapeutics.Pan-Caspase Inhibitors in Huntington’s Disease Models
PAGE 1189
Huntington’s Disease (HD) is characterized by a mutation in the huntingtin gene encoding an expansion of glutamine repeats
on the N terminus of the huntingtin (Htt) protein. Numerous studies have established cleavage of Htt as a critical pathological
event, and caspases have been identified as enzymes that carry out this cleavage. Leyva et al. report the development of
three pan-caspase inhibitors that block cleavage of Htt. In HD models, these inhibitors rescued striatal and cortical neurons
from cell death. These results confirm the role of caspase-mediated Htt cleavage in HD and further implicate caspases as
promising targets for HD therapeutic development.Blocking C. difficile Toxin Production
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The large glucosylating toxin TcdB is a primary virulence factor of the antibiotic-resistant
pathogenic bacterium Clostridium difficile. Here, Puri et al. screen a focused library of covalent
small molecules to identify potent inhibitors of the toxin cysteine protease domain (CPD),
which autoproteolytically activates the toxin. The authors discover inhibitors potent enough
to block toxin function in cell culture and convert these inhibitors into probes that can monitor
toxin allosteric activation. By solving the crystal structure of inhibitor-bound TcdB CPD, this
study provides a framework for developing antivirulence therapeutics that target C. difficile
infection.Chemistry & Biology 17, November 24, 2010 ª2010 Elsevier Ltd All rights reserved vii
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Development of bioorthogonal ligationmethods has afforded newopportunities to explore small molecule protein interactions
using specific probes of enzymes or reporters of protein modifications. The identification of the proteins that are targeted by
small molecule probes/reporters is essential for these functional studies. Yang et al. present here the synthesis and charac-
terization of selectively cleavable affinity tags for versatile and robust bioorthogonal chemical proteomic studies. The azide/
alkyne-functionalized, ortho-hydroxylated-diazobenzene-cleavable affinity tags enabled selective enrichment and efficient
elution of alkyne- and azide-labeled proteins/peptides from complex mixtures and allowed protein identification and modifi-
cation-site mapping using diverse proteomic platforms.
Broad Spectrum Antibiotic Activity Unmaskedviii Chemistry & Biology 17,PAGE 1223
While natural products have proven to be the most robust source of antibiotics, those with broad
spectrum have become increasingly difficult to identify, and the narrow spectrum of others is typi-
cally assumed to be an intrinsic limitation of their scaffold or target. In contrast, Smith et al. demon-
strate that the apparently narrow spectrum of the arylomycin natural products results not from
intrinsic limitations, but from target mutations. The arylomycins have a much broader spectrum of
activity than previously thought, with an even broader spectrum if optimized to bind their target
with higher affinity.
Engineering Complete Erythromycin A Biosynthesis
PAGE 1232Thebiosynthetic pathway for the complex antibiotic erythromycinAhasbeen reconstituted throughE. colibyZhanget al. Todo
so, the authors designed 23 foreign genes for coordinated expression within an E. coli strain engineered to support biosyn-
thesis. As a result, the most clinically relevant form of erythromycin is now available through a production platform that offers
multiple next-generation engineering opportunities. As anearly step toward this potential, the current systemwas reconfigured
to produce two new erythromycin analogs. Future research will continue to mine this biosynthetic pathway for native and
altered forms of erythromycin to be applied toward established and emerging pathogenic microorganisms.
Affinity Patterns of Small Molecule Kinase Inhibitors
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Interactionsbetweenkinasesandsmallmolecule inhibitorscanbeactivationstatedependent.Wodickaetal. havesystematically
explored the effects of ABL1 activation loop phosphorylation and PDGFR family autoinhibitory juxtamembrane domain docking
on inhibitor binding affinity. For a diverse compound set, the binding affinity patterns correctly classify inhibitors as having type I
and type II binding modes, and the authors show that juxtamembrane domain docking can have dramatic negative effects on
inhibitor affinity. The results have allowed authors to associate ligand-induced conformational changes observed in cocrystal
structures with specific energetic costs. The approach described should facilitate indication-specific kinase inhibitor design.O-GlcNAcase Inhibitors with Selective Tastes
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O-GlcNAc is a posttranslational modification that regulates several cellular processes in metazoa. The
work by Dorfmueller et al. describes the design of chemical tools that inhibit O-GlcNAcase in live cells
and canbe used to study the role ofO-GlcNAc in signal transduction pathways. The inhibitors, GlcNAc-
statin derivatives, are nanomolar inhibitors of the enzymeand93105-fold selective over the structurally
related lysozomal hexosaminidases. These small molecules are shown to be cell-penetrant and raise
cellular O-GlcNAc levels when applied at low nanomolar concentrations and are thus valuable tools
for studying the role ofO-GlcNAc in a range of cellular processes.
Normalizing Cardiovascular Function in Hypertension
through FAAH Inhibition
PAGE 1256
Godlewski et al. developed a compound, AM3506, which normalizes the elevated blood pressure and cardiac function in
hypertensive rats. These effects are due to blockade of fatty-acid amide hydrolase (FAAH): an enzyme that catalyzes the
degradation of endocannabinoid anandamide and controls its action at cannabinoid receptors in brain and liver. AM3506
is able to block FAAH activity in the brain without affecting the liver enzyme and, therefore, is devoid of unwanted metabolic
effects observed in obesity, e.g., increased blood glucose level (hyperglycemia). This unique activity profile of AM356makes it
attractive for potential therapeutic use as an antihypertensive in obese subjects.November 24, 2010 ª2010 Elsevier Ltd All rights reserved
